THERANOSTICS 2016*
Chairs: Harvey Turner & Grace Kong
Sponsored by:
Two Decades of THERANOSTICS in Neuroendocrine Tumors – Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT) (#8)
1:00 PM
NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis (#9)
1:30 PM
Clinical Perspective: The “difficult development situation”: how to approach and overcome challenges from a regulatory perspective (#10)
2:00 PM
The Cruel Wait for PRRT (#11)
2:30 PM
The challenges of waiting for RCTs vs treating patients now (#12)
2:45 PM